ORIGINAL_ARTICLE
Subclinical left ventricular systolic dysfunction in patients with metabolic syndrome: A case–control study using two-dimensional speckle tracking echocardiography
BACKGROUND: The dramatic increase in the prevalence of metabolic syndrome is associated with more increased cardiovascular morbidity and mortality in this group. Some recent studies suggested that metabolic syndrome is associated with increased risk of subclinical left ventricular (LV) systolic dysfunction. In the present cross-sectional case–control study, the utility of two-dimensional speckle tracking echocardiography (STE) was examined to detect early LV systolic dysfunction in this population. METHODS: A total of 75 clinically asymptomatic subjects with LV ejection fraction (LVEF) ≥ 55%, 39 without metabolic syndrome and 36 with metabolic syndrome, matched for gender and age, were enrolled in this case–control study. Metabolic syndrome was diagnosed using the National Cholesterol Education Program/Adult Treatment Panel III criteria. LV systolic function was assessed by STE-derived global and segmental longitudinal strain (εLL). RESULTS: Global εLL was significantly lower in patients with metabolic syndrome compared with normal population (−18.41 ± 2.20% vs. −21.2 ± 2.1%, P < 0.001). Segmental εLL was significantly lower in patients with metabolic syndrome in comparison to control group except for basal anteroseptal (−19.95 ± 2.90% vs. −21.15 ± 3.30%, P = 0.106), basal anterolateral (−17.5 ± 5.0% vs. −18.3 ± 4.1%, P = 0.437), and basal inferolateral segments (−18.1 ± 6.3% vs. −18.9 ± 4.1%, P = 0.526). CONCLUSION: STE-derived longitudinal LV strain (εLL), a marker of subclinical cardiovascular disease, is impaired in asymptomatic individuals with metabolic syndrome and normal LVEF.
https://arya.mui.ac.ir/article_10552_bd970e1f4e9b7dbfb7f025ec585c6a50.pdf
2016-11-01
254
258
Metabolic Syndrome
Two-dimensional Echocardiography
Systole
Ventricular Dysfunction
Asymptomatic Disease
Alireza
Moaref
moarefa@sums.ac.ir
1
Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Majid
Faraji
2
Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Maryam
Tahamtan
mtahamtan@sums.ac.ir
3
Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
Kim JY, Mun HS, Lee BK, Yoon SB, Choi EY, Min PK, et al. Impact of metabolic syndrome and its individual components on the presence and severity of angiographic coronary artery disease. Yonsei Med J 2010; 51(5): 676-82.
1
Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006; 113(25): 2943-6.
2
Levesque J, Lamarche B. The metabolic syndrome: definitions, prevalence and management. J Nutrigenet Nutrigenomics 2008; 1(3): 100-8.
3
Nesbitt GC, Mankad S, Oh JK. Strain imaging in echocardiography: methods and clinical applications. Int J Cardiovasc Imaging 2009; 25(Suppl 1): 9-22.
4
Imbalzano E, Zito C, Carerj S, Oreto G, Mandraffino G, Cusma-Piccione M, et al. Left ventricular function in hypertension: new insight by speckle tracking echocardiography. Echocardiography 2011; 28(6): 649-57.
5
Yoon JH, Kim HJ, Lee EJ, Moon S, Lee JY, Lee JW, et al. Early left ventricular dysfunction in children after hematopoietic stem cell transplantation for acute leukemia: a case control study using speckle tracking echocardiography. Korean Circ J 2015; 45(1): 51-8.
6
Voulgari C, Moyssakis I, Papazafiropoulou A, Perrea D, Kyriaki D, Katsilambros N, et al. The impact of metabolic syndrome on left ventricular myocardial performance. Diabetes Metab Res Rev 2010; 26(2): 121-7.
7
Gong HP, Tan HW, Fang NN, Song T, Li SH, Zhong M, et al. Impaired left ventricular systolic and diastolic function in patients with metabolic syndrome as assessed by strain and strain rate imaging. Diabetes Res Clin Pract 2009; 83(3): 300-7.
8
Almeida AL, Teixido-Tura G, Choi EY, Opdahl A, Fernandes VR, Wu CO, et al. Metabolic syndrome, strain, and reduced myocardial function: multi-ethnic study of atherosclerosis. Arq Bras Cardiol 2014; 102(4): 327-35.
9
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735-52.
10
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28(1): 1-39.
11
Pacholczyk M, Ferenc T, Kowalski J. The metabolic syndrome. Part I: definitions and diagnostic criteria for its identification. Epidemiology and relationship with cardiovascular and type 2 diabetes risk. Postepy Hig Med Dosw (Online) 2008; 62: 530-42.
12
Sreenivasa Kumar ML, Rajasekhar D, Vanajakshamma V, Latheef K. Impact of metabolic syndrome on global left ventricular function: As evaluated by the myocardial performance index. J Saudi Heart Assoc 2014; 26(3): 145-51.
13
Wang Q, Sun QW, Wu D, Yang MW, Li RJ, Jiang B, et al. Early detection of regional and global left ventricular myocardial function using strain and strain-rate imaging in patients with metabolic syndrome. Chin Med J (Engl) 2015; 128(2): 226-32.
14
Hanekom L, Cho GY, Leano R, Jeffriess L, Marwick TH. Comparison of two-dimensional speckle and tissue Doppler strain measurement during dobutamine stress echocardiography: an angiographic correlation. Eur Heart J 2007; 28(14): 1765-72.
15
Leitman M, Lysiansky M, Lysyansky P, Friedman Z, Tyomkin V, Fuchs T, et al. Circumferential and longitudinal strain in 3 myocardial layers in normal subjects and in patients with regional left ventricular dysfunction. J Am Soc Echocardiogr 2010; 23(1): 64-70.
16
ORIGINAL_ARTICLE
The prevalence of hypertension and its relationship with demographic factors, biochemical, and anthropometric indicators: A population-based study
BACKGROUND: Hypertension (HTN) is an important public health challenge worldwide. The prevalence of HTN varies across countries. It is necessary to obtain valid information about the prevalence of chronic condition like HTN and its predictors in different societies. Hence, this study was conducted to assess the prevalence of HTN and associated factors in Mashhad, Iran, 2015. METHODS: This cross-sectional study was performed on 2974 adults residing in Mashhad in 2015. Multistage random sampling was used. A checklist was fulfilled for each subject, and a blood sample was taken for measuring fasting blood sugar, total cholesterol, triglycerides, hemoglobin, serum creatinine, high-density lipoproteins, and low-density lipoproteins. The height and weight of participants and their blood pressure were measured according to protocols. RESULTS: The prevalence of HTN in this population was 22% (25.9% in male and 20% in female). Most interestingly, smoking and drug abuse were more prevalent in men (14.9% and 3.8%), but the sedentary behavior was more prevalent in women (51%). Interestingly, by increasing the age, the frequency of optimum, normal and high normal type was decreased and the frequency of HTN, specially sever form were increased. In binary logistic regression model, age [odds ratio (OR): 1.07, 95% confidence interval (CI): 1.06-1.09], gender (Ref:Female) (OR: 1.39, 95% CI: 1.05-1.83), and obesity (OR: 1.09, 95% CI: 1.06-1.12) were the predictors of HTN. CONCLUSION: The prevalence of HTN among this population was found to be high; which indicates the need for HTN-screening programs, especially for the elderly, male and obese population. Given the close relationship between obesity and various diseases, including HTN, practical solutions, including lifestyle interventions, need to be developed.
https://arya.mui.ac.ir/article_10553_5a2f6675cdc2600ae8f2fb3351e7a270.pdf
2017-02-01
259
265
Hypertension
Prevalence
Adult
Anthropometric Indicators
Mohammad
Khajedaluee
1
Professor, Department of Community Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Tahereh
Hassannia
2
Department of Internal Medicine, School of Medicine, Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Abdolrahim
Rezaee
3
Assistant Professor, Inflammation and Inflammatory Diseases Research Center AND Department of Immunology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Maryam
Ziadi
4
State Health Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Maliheh
Dadgarmoghaddam
dadgarmm@mums.ac.ir
5
Assistant Professor, Department of Community Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Mohan S, Campbell N, Chockalingam A. Time to effectively address hypertension in India. Indian J Med Res 2013; 137(4): 627-31.
1
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507-20.
2
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-13.
3
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-72.
4
Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22(1): 11-9.
5
Haghdoost AA, Sadeghirad B, Rezazadehkermani M. Epidemiology and heterogeneity of hypertension in Iran: a systematic review. Arch Iran Med 2008; 11(4): 444-52.
6
Veghari G, Sedaghat M, Maghsodlo S, Banihashem S, Moharloei P, Angizeh A, et al. Impact of Literacy on the Prevalence, Awareness, Treatment andControl of Hypertension in Iran. J Cardiovasc Thorac Res 2012; 4(2): 37-40.
7
Sahraki R, Mirshekari M, Sahraki H, Mohammadi AR, Sahraki M, Khazaei Feizabad E. Hypertension Among 30+ Year-Old People in Zahedan (Southeast of Iran). Shiraz E Med J 2011; 12(3): 129-34.
8
Namayandeh S, Sadr S, Rafiei M, Modares-Mosadegh M, Rajaefard M. Hypertension in Iranian urban population, epidemiology, awareness, treatment and control. Iran J Public Health 2011; 40(3): 63-70.
9
Azizi F, Esmaillzadeh A, Mirmiran P. Obesity and cardiovascular disease risk factors in Tehran adults: a population-based study. East Mediterr Health J 2004; 10(6): 887-97.
10
Peymani P, Heydari ST, Ahmadi SM, Lankarani KB. The prevalence of high blood pressure and its relationship with anthropometric indicators; a population based study in Fars Province, IR Iran. J Cardiovasc Thorac Res 2012; 6(2): 40-5.
11
Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, et al. Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health 2009; 9: 167.
12
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care
13
; 31(Suppl): S55-S60.
14
Taylor RB. Family medicine: principles and practice. 5th ed. Berline, Germany: Springer Science & Business Media; 2013.
15
Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 2011; 57(20): 2037-114.
16
Cheraghian B, Asadi-Lari M, Mansournia MA, Majdzadeh R, Mohammad K, Nedjat S, et al. Prevalence and associated factors of self-reported hypertension among Tehran adults in 2011: a population-based study (Urban HEART-2). Med J Islam Repub Iran 2014; 28: 105.
17
Sarry El-Din A, Erfan M, Kandeel W, Kamal S, El Banna R, Fouad W. Prevalence of pre-hypertension and hypertension in a sample of egyptian adults and its relation to obesity. Aust J Basic Appl Sci 2012; 6(13): 481-9.
18
Shapo L, Pomerleau J, McKee M. Epidemiology of hypertension and associated cardiovascular risk factors in a country in transition: a population based survey in Tirana City, Albania. J Epidemiol Community Health 2003; 57(9): 734-9.
19
Manandhar K, Koju R, Sinha NP, Humagain S. Prevalence and associated risk factors of hypertension among people aged 50 years and more in Banepa Municipality, Nepal. Kathmandu Univ Med J (KUMJ) 2012; 10(39): 35-8.
20
Azizi F, Ghanbarian A, Madjid M, Rahmani M. Distribution of blood pressure and prevalence of hypertension in Tehran adult population: Tehran Lipid and Glucose Study (TLGS), 1999-2000. J Hum Hypertens 2002; 16(5): 305-12.
21
Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens 2004; 18(2): 73-8.
22
Hatmi ZN, Tahvildari S, Gafarzadeh MA, Sabouri KA. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord 2007; 7: 32.
23
Dogan N, Toprak D, Demir S. Hypertension prevalence and risk factors among adult population
24
in Afyonkarahisar region: a cross-sectional research. Anadolu Kardiyol Derg 2012; 12(1): 47-52.
25
Colin BA, Adair LS, Popkin BM. Ethnic differences in the association between body mass index and hypertension. Am J Epidemiol 2002; 155(4): 346-53.
26
Nielsen GA, Andersen LB. The association between high blood pressure, physical fitness, and body mass index in adolescents. Prev Med 2003; 36(2): 229-34.
27
Guagnano MT, Ballone E, Pace-Palitti V, Vecchia RD, D'Orazio N, Manigrasso MR, et al. Risk factors for hypertension in obese women. The role of weight cycling. Eur J Clin Nutr 2000; 54(4): 356-60.
28
Amirkhizi F, Siassi F, Minaie S, Jalali M, Dorosty Motlagh A R, Chamari M. Assessment of blood pressure status and its relationship with anthropometric indices among women in rural areas of Kerman province, Iran. Yafteh 2009; 10(2): 31-8.
29
Primatesta P, Falaschetti E, Gupta S, Marmot MG, Poulter NR. Association between smoking and blood pressure: evidence from the health survey for England. Hypertension 2001; 37(2): 187-93.
30
Beunza JJ, Martinez-Gonzalez MA, Ebrahim S, Bes-Rastrollo M, Nunez J, Martinez JA, et al. Sedentary behaviors and the risk of incident hypertension: the SUN Cohort. Am J Hypertens 2007; 20(11): 1156-62.
31
Ordunez P, Munoz JL, Espinosa-Brito A, Silva LC, Cooper RS. Ethnicity, education, and blood pressure in Cuba. Am J Epidemiol 2005; 162(1): 49-56.
32
Xu X, Niu T, Christiani DC, Weiss ST, Zhou Y, Chen C, et al. Environmental and occupational determinants of blood pressure in rural communities in China. Ann Epidemiol 1997; 7(2): 95-106.
33
Gharipour M, Khosravi A, Sadeghi M, Roohafza H, Hashemi M, Sarrafzadegan N. Socioeconomic characteristics and controlled hypertension: Evidence from Isfahan Healthy Heart Program. ARYA Atheroscler 2013; 9(1): 77-81.
34
Dadgarmoghaddam M, Khajedaluee M, Khadem Rezaiyan M, Khodaee G. Risk factors for non-communicable disease: a population based study in Mashhad (Iran). Br J Med Med Res 2015; 7(6): 503-11.
35
ORIGINAL_ARTICLE
Comparative effects of carbohydrate versus fat restriction on metabolic profiles, biomarkers of inflammation and oxidative stress in overweight patients with Type 2 diabetic and coronary heart disease: a randomized clinical trialComparative effects of car
BACKGROUND: This study was conducted to establish the comparative effects of carbohydrate versus fat restriction on metabolic indices in Type 2 diabetic (T2D) patients with coronary heart disease (CHD). METHODS: This randomized, clinical trial was done among 56 overweight persons with T2D and CHD aged 40-85 years old. The patients were randomly allocated to take either a high-carbohydrate (HC) diet (60-65% carbohydrates and 20-25% fats) (n = 28) or a restricted carbohydrate (RC) diet (43-49% carbohydrate and 36-40% fats) (n = 28) for 8 weeks to determine metabolic status. RESULTS: After 8 weeks of treatment, RC diet decreased fasting plasma glucose (FPG) (−11.5 ± 28.3 vs. +7.0 ± 26.9 mg/dl, P = 0.010) and high-sensitivity C-reactive protein (hs-CRP) (−564.3 ± 1280.1 vs. +286.1 ± 1789.2 ng/ml, P = 0.040) compared with a HC diet. Moreover, compared with a HC diet, RC diet increased total antioxidant capacity (TAC) (+274.8 ± 111.5 vs. +20.2 ± 82.5 mmol/l, P < 0.001) and glutathione (GSH) levels (+51.6 ± 111.5 vs. −32.6 ± 88.5 µmol/l, P = 0.003). No significant alterations between the two groups were found in terms of their effect on other metabolic profiles. CONCLUSION: RC diet in overweight T2D with CHD had beneficial effects on FPG, hs-CRP, TAC, and GSH values.
https://arya.mui.ac.ir/article_10554_c9259822810ac1c054d6249f1228f7b5.pdf
2017-02-18
266
273
Carbohydrate Restriction
Metabolic Status
Type 2 Diabetes Mellitus
Coronary Heart Disease
Obesity
Fariba
Raygan
1
Department of Cardiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Fereshteh
Bahmani
2
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Ebrahim
Kouchaki
3
Physiology Research Center AND Department of Neurology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Esmat
Aghadavod
4
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Sahar
Sharifi
5
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Elmira
Akbari
6
Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Akbar
Heidari
7
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran
AUTHOR
Zatollah
Asemi
asemi_r@yahoo.com
8
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran
LEAD_AUTHOR
Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87(3): 293-301.
1
Ades PA, Savage PD. Potential benefits of weight loss in coronary heart disease. Prog Cardiovasc Dis 2014; 56(4): 448-56.
2
Garcia-Bailo B, El-Sohemy A, Haddad PS, Arora P, Benzaied F, Karmali M, et al. Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress. Biologics 2011; 5: 7-19.
3
Kotur-Stevuljevic J, Memon L, Stefanovic A, Spasic S, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N, et al. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin Biochem 2007; 40(3-4): 181-7.
4
Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013; 34(31): 2436-43.
5
von Bibra H, St John Sutton M, Schuster T, Ceriello A, Siegmund T, Schumm-Draeger PM. Oxidative stress after a carbohydrate meal contributes to the deterioration of diastolic cardiac function in nonhypertensive insulin-treated patients with moderately well controlled type 2 diabetes. Horm Metab Res 2013; 45(6): 449-55.
6
Zhang X, Yan SM, Zheng HL, Hu DH, Zhang YT, Guan QH, et al. A mechanism underlying hypertensive occurrence in the metabolic syndrome: cooperative effect of oxidative stress and calcium accumulation in vascular smooth muscle cells. Horm Metab Res 2014; 46(2): 126-32.
7
Feinman RD, Volek JS. Carbohydrate restriction as the default treatment for type 2 diabetes and metabolic syndrome. Scand Cardiovasc J 2008; 42(4): 256-63.
8
Muzio F, Mondazzi L, Harris WS, Sommariva D, Branchi A. Effects of moderate variations in the macronutrient content of the diet on cardiovascular disease risk factors in obese patients with the metabolic syndrome. Am J Clin Nutr 2007; 86(4): 946-51.
9
Parillo M, Rivellese AA, Ciardullo AV, Capaldo B, Giacco A, Genovese S, et al. A high-monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients. Metabolism 1992; 41(12): 1373-8.
10
Jonasson L, Guldbrand H, Lundberg AK, Nystrom FH. Advice to follow a low-carbohydrate diet has a favourable impact on low-grade inflammation in type 2 diabetes compared with advice to follow a low-fat diet. Ann Med 2014; 46(3): 182-7.
11
Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Sato M, et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32(5): 959-65.
12
Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111(11): 1448-54.
13
Kasim-Karakas SE, Tsodikov A, Singh U, Jialal I. Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. Am J Clin Nutr 2006; 83(4): 774-9.
14
Rajaie S, Azadbakht L, Saneei P, Khazaei M, Esmaillzadeh A. Comparative effects of carbohydrate versus fat restriction on serum levels of adipocytokines, markers of inflammation, and endothelial function among women with the metabolic syndrome: a randomized cross-over clinical trial. Ann Nutr Metab 2013; 63(1-2): 159-67.
15
Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32(9 Suppl): S498-S504.
16
Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37(Suppl 1): S81-S90.
17
Welles CC, Whooley MA, Karumanchi SA, Hod T, Thadhani R, Berg AH, et al. Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol 2014; 179(11): 1279-87.
18
Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT. Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care 2013; 36(4): 845-53.
19
Tatsch E, Bochi GV, Pereira Rda S, Kober H, Agertt VA, de Campos MM, et al. A simple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clin Biochem 2011; 44(4): 348-50.
20
Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: The FRAP assay. Anal Biochem 1996; 239(1): 70-6.
21
Beutler E, Gelbart T. Plasma glutathione in health and in patients with malignant disease. J Lab Clin Med 1985; 105(5): 581-4.
22
Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990; 9(6): 515-40.
23
Volek JS, Phinney SD, Forsythe CE, Quann EE, Wood RJ, Puglisi MJ, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids 2009; 44(4): 297-309.
24
Lachin JM. Fallacies of last observation carried forward analyses. Clin Trials 2016; 13(2): 161-8.
25
Mirhashemi SM, Najafi V, Raygan F, Asemi Z. The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized, double-blind, placebo-controlled trial. ARYA Atheroscler 2016; 12(4): 158-65.
26
Zarei M, Farahnak Z, Hosseinzadeh-Attar MJ, Javanbakht MH, Hosseinzadeh P, Derakhshanian H, et al. Lipid peroxidation and antioxidant enzymes activity in controlled and uncontrolled Type 2 diabetic patients. ARYA Atheroscler 2016; 12(3): 118-23.
27
Ballard KD, Quann EE, Kupchak BR, Volk BM, Kawiecki DM, Fernandez ML, et al. Dietary carbohydrate restriction improves insulin sensitivity, blood pressure, microvascular function, and cellular adhesion markers in individuals taking statins. Nutr Res 2013; 33(11): 905-12.
28
Hickey JT, Hickey L, Yancy WS, Hepburn J, Westman EC. Clinical use of a carbohydrate-restricted diet to treat the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord 2003; 1(3): 227-32.
29
Forsythe CE, Phinney SD, Fernandez ML, Quann EE, Wood RJ, Bibus DM, et al. Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. Lipids 2008; 43(1): 65-77.
30
McLaughlin T, Carter S, Lamendola C, Abbasi F, Yee G, Schaaf P, et al. Effects of moderate
31
variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults. Am J Clin Nutr 2006; 84(4): 813-21.
32
Barbosa KB, Volp AC, Marques-Rocha JL, Ribeiro SM, Navarro-Blasco I, Zulet MA, et al. Low energy and carbohydrate intake associated with higher total antioxidant capacity in apparently healthy adults. Nutrition 2014; 30(11-12): 1349-54.
33
Skalicky J, Muzakova V, Kandar R, Meloun M, Rousar T. Oxidative stress and metabolic syndrome in obese adults with and without controlled diet restriction. Bratisl Lek Listy 2009; 110(3): 152-7.
34
Rankin JW, Turpyn AD. Low carbohydrate, high fat diet increases C-reactive protein during weight loss. J Am Coll Nutr 2007; 26(2): 163-9.
35
Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 2004; 279(17): 16971-9.
36
ORIGINAL_ARTICLE
The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population
BACKGROUND: Fingolimod (FTY-720) has shown efficacy in relapsing multiple sclerosis (MS), while some side effects of this drug have been recognized that the most important is cardiovascular side effects. The aim of this study was to evaluate the cardiovascular side effects of FTY-720. However, the effect of fingolimod on cardiac has not been well recognized. This study was designed to evaluate the cardiovascular side effects of fingolimod in relapsing-remitting multiple sclerosis (RRMS) patient in an Iranian population. METHODS: This prospective clinical trial study was performed on 200 RRMS patients. The patients received a single daily oral dose of fingolimod 0.5 mg. During the first 6 hours after the first fingolimod dose, the patients’ vital signs and electrocardiographic traces were continuously monitored. Moreover, the patients followed up over 6 months after receiving fingolimod. RESULTS: The results showed that pulse rate (P < 0.001), systolic blood pressure (BP) (P < 0.001), and diastolic BP (P < 0.001) were decreased significantly during 6 hours after receiving the first dose of fingolimod. The most reduction in vital sign was observed in 3 hours. Arrhythmia, bradycardia, and dizziness were the other complications of fingolimod, which were detected in our study. CONCLUSION: All the side effects such as hypotension and bradycardia were happened in first 3 hours after receiving the fingolimod. Indeed, we advise clinicians to monitor the patients for first 6 hours after initiation of fingolimod to decrease worse side effects.
https://arya.mui.ac.ir/article_10555_45a235a947937cd766ab2b8472816aed.pdf
2017-03-05
274
280
Fingolimod
Cardiovascular
Side Effect
Multiple Sclerosis
Morteza
Abdar
abdar@med.mui.ac.ir
1
Professor, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Payam
Ebrahimifar
payame1383@yahoo.com
2
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
Masoud
Etemadifar
3
Professor, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Kay M, Hojati Z, Dehghanian F. The molecular study of IFNbeta pleiotropic roles in MS treatment. Iran J Neurol 2013; 12(4): 149-56.
1
Ayatollahi A, Mohajeri-Tehrani MR, Nafissi S. Factors affecting bone mineral density in multiple sclerosis patients. Iran J Neurol 2013; 12(1): 19-22.
2
Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9(5): 520-32.
3
Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C. Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. Ther Clin Risk Manag 2013; 9: 73-85.
4
Fazekas F, Bajenaru O, Berger T, Fabjan TH, Ledinek AH, Jakab G, et al. How does fingolimod (gilenya((R))) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol 2013; 4: 10.
5
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-15.
6
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 387-401.
7
Sato DK, Nakashima I, Bar-Or A, Misu T, Suzuki C, Nishiyama S, et al. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. J Neuroimmunol 2014; 268(1-2): 95-8.
8
Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005; 5(3): 529-36.
9
Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355(11): 1124-40.
10
DiMarco J, O'Connor P, Cohen J, Reder A, Zhang-Auberson L, Tang D, et al. Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies. Mult Scler 2012; 18(Suppl 4): 55-227.
11
Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 2009; 82(2): 193-200.
12
Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 2011; 108(2): 751-6.
13
Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63(1): 61-71.
14
Egom EE, Ke Y, Musa H, Mohamed TM, Wang T, Cartwright E, et al. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol 2010; 48(2): 406-14.
15
Krishna R, St-Louis M, Mayer LD. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer 2000; 85(1): 131-41.
16
Fragoso YD, Arruda CC, Arruda WO, Brooks JB, Damasceno A, Damasceno CA, et al. The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis. Arq Neuropsiquiatr 2014; 72(9): 712-4.
17
Szeplaki G, Merkely B. Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis. Ideggyogy Sz 2012; 65(11-12): 369-76.
18
Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci U S A 2012; 109(39): 15930-5.
19
Keul P, Lucke S, von Wnuck Lipinski K, Bode C, Graler M, Heusch G, et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res 2011; 108(3): 314-23.
20
Kovarik JM, Slade A, Riviere GJ, Neddermann D, Maton S, Hunt TL, et al. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. Br J Clin Pharmacol 2008; 66(2): 199-206.
21
Lee CW, Choi JW, Chun J. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. Arch Pharm Res 2010; 33(10): 1567-74.
22
Cuvillier O. Sphingosine 1-phosphate receptors: from biology to physiopathology. Med Sci (Paris) 2012; 28(11): 951-7.
23
Fryer RM, Muthukumarana A, Harrison PC, Nodop MS, Chen RR, Harrington KE, et al. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P(1)) and hypertension (S1P(3)) in rat. PLoS One 2012; 7(12): e52985.
24
ORIGINAL_ARTICLE
Review of studies on the fat mass and obesity-associated (FTO) gene interactions with environmental factors affecting on obesity and its impact on lifestyle interventions
BACKGROUND: The prevalence of obesity is influenced by environmental and genetic factors. Recently, it has been reported that an interaction between genotype and environmental factors can affect each other’s effects on the phenotype. The purpose of this study is to evaluate the recent studies on the fat mass and obesity-associated (FTO) gene interactions with environmental factors affecting on obesity and the impact of these interactions on the success level of the lifestyle intervention. METHODS: All articles published in English from June 1990 to June 2015 were studied. RESULTS: In most studies, the role of the FTO risk alleles for obesity is significantly intensified through reduced physical activity and high calorie diet. Furthermore, the results of studies about the effect of FTO on the success level of lifestyle interventions have been contradictory. Some studies show that FTO genotype influences on the success of lifestyle interventions, while other studies did not report it. CONCLUSION: The results of these studies generally indicate that the effect of the FTO gene on obesity may be influenced by environmental factors and lifestyle. In the other hand, the FTO genotype can affect the success of lifestyle interventions in the prevention and treatment of obesity. Future studies are crucial to elucidate relationships between FTO gene and lifestyle.
https://arya.mui.ac.ir/article_10556_2253aa9bf498d4ab9f85ad7ac50781da.pdf
2017-02-01
281
290
Fat Mass and Obesity Gene
Life Style
Obesity
Naser
Kalantari
1
Associate Professor, Department of Community Nutrition, School of Nutrition and Food Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Saeid
Doaei
sdoaei@sbmu.ac.ir
2
Students Research Committee, National Nutrition and Food Technology Research Institute AND Department of Community Nutrition, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Nastaran
Keshavarz-Mohammadi
3
Associate Professor, Department of Public Health, School of Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Maryam
Gholamalizadeh
mgholamalizade84@yahoo.com
4
PhD Student, Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
AUTHOR
Naeimeh
Pazan
5
Department of Veterinary Medicine, School of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran
AUTHOR
World Health Organization. Obesity: preventing and managing the global epidemic. Geneva, Switzerland: World Health Organization; 2000.
1
Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults (U.S.). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Washington, DC: National Institutes of Health, National Heart, Lung, and Blood Institute; 1998.
2
Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998; 6(2): 97-106.
3
Wolf AM. What is the economic case for treating obesity? Obes Res 1998; 6(Suppl 1): 2S-7S.
4
Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 2009; 28(5): w822-w831.
5
Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311(8): 806-14.
6
National Center for Health Statistics. Health, United States, 2011: With Special Feature on Socioeconomic Status and Health. Hyattsville, MD: Department of Health and Human Services; 2012.
7
Mirzazadeh A, Sadeghirad B, Haghdoost AA, Bahreini F, Rezazadeh Kermani M. The Prevalence of Obesity in Iran in Recent Decade; a Systematic Review and Meta-Analysis Study. Iranian J Publ Health 2009; 38(3): 1-11.
8
Office of the Surgeon General (US), Office of Disease Prevention and Health Promotion (US). The Surgeon General's Call To Action To Prevent and Decrease Overweight and Obesity. Rockville, MD: Office of the Surgeon General (US); 2001.
9
Centre for Public Health Excellence at NICE, National Collaborating Centre for Primary Care. Obesity: The Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children [Internet]. London, UK: National Institute for Health and Clinical Excellence; 2006.
10
Swanton K. Healthy weight, healthy lives: A toolkit for developing local strategies. London, UK: Faculty of Public Health; 2006.
11
Amorim AR, Linne YM, Lourenco PM. Diet or exercise, or both, for weight reduction in women after childbirth. Cochrane Database Syst Rev 2007; (3): CD005627.
12
Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev 2005; (2): CD005270.
13
Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev 2006; (4): CD003817.
14
Roberts K, Cavill N, Rutter H. Standard Evaluation Framework for weight management interventions. Oxford, UK: National Obesity Observatory; 2009.
15
National Institute for Health and Clinical Excellence. Behaviour Change: the Principles for Effective Interventions NICE Public Health Guidance. London, UK: National Institute for Health and Clinical Excellence; 2007.
16
Weiss R. Cardiovascular risk clustering in obese children. In: Bagchi D, Editor. Global Perspectives on Childhood Obesity: Current Status, Consequences and Prevention. Cambridge, MA: Academic Press; 2010. p. 139-46.
17
Logue J, Thompson L, Romanes F, Wilson DC, Thompson J, Sattar N. Management of obesity: summary of SIGN guideline. BMJ 2010; 340: c154.
18
World Health Organization. The Ottawa Charter for Health Promotion [Online]. [cited 1986]; Available from: URL:
19
http://www.who.int/healthpromotion/conferences/previous/ottawa/en/index4.html
20
Tyrrell VJ, Richards GE, Hofman P, Gillies GF, Robinson E, Cutfield WS. Obesity in Auckland school children: a comparison of the body mass index and percentage body fat as the diagnostic criterion. Int J Obes Relat Metab Disord 2001; 25(2): 164-9.
21
Reinehr T. Lifestyle intervention in childhood obesity: changes and challenges. Nat Rev Endocrinol 2013; 9(10): 607-14.
22
Gabriele JM, Stewart TM, Sample A, Davis AB, Allen R, Martin CK, et al. Development of an internet-based obesity prevention program for children. J Diabetes Sci Technol 2010; 4(3): 723-32.
23
Williamson DA, Champagne CM, Harsha DW, Han H, Martin CK, Newton RL Jr., et al. Effect of an environmental school-based obesity prevention program on changes in body fat and body weight: a randomized trial. Obesity (Silver Spring) 2012; 20(8): 1653-61.
24
Loos RJ. Genetic determinants of common obesity-susceptibility. In: Symonds ME, Editor. Adipose tissue biology. Berlin, Germany: Springer Science & Business Media; 2011. p. 317-37.
25
Doaee S, Gholamalizadeh M. Polymorphism of A I, A IV and E Apolipoprotein Genes and Effect of Fat Intake on HDL Levels. G3 M2011; 9(1): 2323-8.
26
Doaei S, Kalantari N, Keshavarz Mohammadi N, Azizi Tabesh G, Gholamalizadeh M. Macronutrients and the FTO gene expression in hypothalamus; a systematic review of experimental studies. Indian Heart J 2017; 69(2): 277-81.
27
Doaei S, Gholamalizadeh M, Akbari M, Safavi SM. Nutritional genomics: a window to the future. 1st ed. Qom, Iran: Andishe Mandegar Publications; 2011. p. 5-9. [In Persian].
28
Doaei S, Gholamalizadeh M. The association of genetic variations with sensitivity of blood pressure to dietary salt: A narrative literature review. ARYA Atheroscler 2014; 10(3): 169-74.
29
Safavi SM, Doaei S, Gholamalizadeh M. Unsaid of nutrition and genetics. The World of Nutrition Journal 2007; 6(60): 22-3.
30
Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316(5826): 889-94.
31
Chagnon YC, Rankinen T, Snyder EE, Weisnagel SJ, Perusse L, Bouchard C. The human obesity gene map: the 2002 update. Obes Res 2003; 11(3): 313-67.
32
Perusse L, Bouchard C. Identification of genes contributing to excess body fat and fat distribution. Proceedings of the 7th International Congress on Obesity; 1994 Aug 20-25; Toronto, ON.
33
Challis BG, Luan J, Keogh J, Wareham NJ, Farooqi IS, O'Rahilly S. Genetic variation in the corticotrophin-releasing factor receptors: identification of single-nucleotide polymorphisms and association studies with obesity in UK Caucasians. Int J Obes Relat Metab Disord 2004; 28(3): 442-6.
34
Gibson WT, Pissios P, Trombly DJ, Luan J, Keogh J, Wareham NJ, et al. Melanin-concentrating hormone receptor mutations and human obesity: functional analysis. Obes Res 2004; 12(5): 743-9.
35
Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387(6636): 903-8.
36
Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003; 348(12): 1085-95.
37
Zhang X, Qi Q, Zhang C, Smith SR, Hu FB, Sacks FM, et al. FTO genotype and 2-year change in body composition and fat distribution in response to weight-loss diets: the POUNDS LOST Trial. Diabetes 2012; 61(11): 3005-11.
38
Cecil JE, Tavendale R, Watt P, Hetherington MM, Palmer CN. An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med 2008; 359(24): 2558-66.
39
Church C, Moir L, McMurray F, Girard C, Banks GT, Teboul L, et al. Overexpression of Fto leads to increased food intake and results in obesity. Nat Genet 2010; 42(12): 1086-92.
40
Ahmad T, Chasman DI, Mora S, Pare G, Cook NR, Buring JE, et al. The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. Am Heart J 2010; 160(6): 1163-9.
41
Hardy R, Wills AK, Wong A, Elks CE, Wareham NJ, Loos RJ, et al. Life course variations in the associations between FTO and MC4R gene variants and body size. Hum Mol Genet 2010; 19(3): 545-52.
42
Hakanen M, Raitakari OT, Lehtimaki T, Peltonen N, Pahkala K, Sillanmaki L, et al. FTO genotype is associated with body mass index after the age of seven years but not with energy intake or leisure-time physical activity. J Clin Endocrinol Metab 2009; 94(4): 1281-7.
43
Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gomez-Marin C, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature 2014; 507(7492): 371-5.
44
Vimaleswaran KS, Li S, Zhao JH, Luan J, Bingham SA, Khaw KT, et al. Physical activity attenuates the body mass index-increasing influence of genetic variation in the FTO gene. Am J Clin Nutr 2009; 90(2): 425-8.
45
Andreasen CH, Stender-Petersen KL, Mogensen MS, Torekov SS, Wegner L, Andersen G, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 2008; 57(1): 95-101.
46
Jonsson A, Renstrom F, Lyssenko V, Brito EC, Isomaa B, Berglund G, et al. Assessing the effect of interaction between an FTO variant (rs9939609) and physical activity on obesity in 15,925 Swedish and 2,511 Finnish adults. Diabetologia 2009; 52(7): 1334-8.
47
Corella D, Ortega-Azorin C, Sorli JV, Covas MI, Carrasco P, Salas-Salvado J, et al. Statistical and biological gene-lifestyle interactions of MC4R and FTO with diet and physical activity on obesity: new effects on alcohol consumption. PLoS One 2012; 7(12): e52344.
48
O'Rahilly S, Farooqi IS. Human obesity: a heritable neurobehavioral disorder that is highly sensitive to environmental conditions. Diabetes 2008; 57(11): 2905-10.
49
Tung YC, Yeo GS. From GWAS to biology: lessons from FTO. Ann N Y Acad Sci 2011; 1220: 162-71.
50
Groop L. From fused toes in mice to human obesity. Nat Genet 2007; 39(6): 706-7.
51
Peters T, Ausmeier K, Ruther U. Cloning of Fatso (Fto), a novel gene deleted by the Fused toes (Ft) mouse mutation. Mamm Genome 1999; 10(10): 983-6.
52
Kim B, Kim Y, Cooke PS, Ruther U, Jorgensen JS. The fused toes locus is essential for somatic-germ cell interactions that foster germ cell maturation in developing gonads in mice. Biol Reprod 2011; 84(5): 1024-32.
53
Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 2011; 7(12): 885-7.
54
Boissel S, Reish O, Proulx K, Kawagoe-Takaki H, Sedgwick B, Yeo GS, et al. Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. Am J Hum Genet 2009; 85(1):106-11.
55
Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, Hewitson KS, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 2007; 318(5855): 1469-72.
56
Freathy RM, Timpson NJ, Lawlor DA, Pouta A, Ben-Shlomo Y, Ruokonen A, et al. Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes 2008; 57(5): 1419-26.
57
Speakman JR, Rance KA, Johnstone AM. Polymorphisms of the FTO gene are associated with variation in energy intake, but not energy expenditure. Obesity (Silver Spring) 2008; 16(8): 1961-5.
58
Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 2007; 39(6): 724-6.
59
Timpson NJ, Emmett PM, Frayling TM, Rogers I, Hattersley AT, McCarthy MI, et al. The fat mass- and obesity-associated locus and dietary intake in children. Am J Clin Nutr 2008; 88(4): 971-8.
60
Do R, Bailey SD, Desbiens K, Belisle A, Montpetit A, Bouchard C, et al. Genetic variants of FTO influence adiposity, insulin sensitivity, leptin levels, and resting metabolic rate in the Quebec Family Study. Diabetes 2008; 57(4): 1147-50.
61
Claussnitzer M, Dankel SN, Kim KH, Quon G, Meuleman W, Haugen C, et al. FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. N Engl J Med 2015; 373: 895-907.
62
Rampersaud E, Mitchell BD, Pollin TI, Fu M, Shen H, O'Connell JR, et al. Physical activity and the association of common FTO gene variants with body mass index and obesity. Arch Intern Med 2008; 168(16): 1791-7.
63
Scott RA, Bailey ME, Moran CN, Wilson RH, Fuku N, Tanaka M, et al. FTO genotype and adiposity in children: physical activity levels influence the effect of the risk genotype in adolescent males. Eur J Hum Genet 2010; 18(12): 1339-43.
64
Hubacek JA, Pikhart H, Peasey A, Kubinova R, Bobak M. FTO variant, energy intake, physical activity and basal metabolic rate in Caucasians. The HAPIEE study. Physiol Res 2011; 60(1): 175-83.
65
Ahmad T, Lee IM, Pare G, Chasman DI, Rose L, Ridker PM, et al. Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. women. Diabetes Care 2011; 34(3): 675-80.
66
Kilpelainen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E, et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med 2011; 8(11): e1001116.
67
Ruiz JR, Labayen I, Ortega FB, Legry V, Moreno LA, Dallongeville J, et al. Attenuation of the effect of the FTO rs9939609 polymorphism on total and central body fat by physical activity in adolescents: the HELENA study. Arch Pediatr Adolesc Med 2010; 164(4): 328-33.
68
Haupt A, Thamer C, Machann J, Kirchhoff K, Stefan N, Tschritter O, et al. Impact of variation in the FTO gene on whole body fat distribution, ectopic fat, and weight loss. Obesity (Silver Spring) 2008; 16(8): 1969-72.
69
Lappalainen TJ, Tolppanen AM, Kolehmainen M, Schwab U, Lindstrom J, Tuomilehto J, et al. The common variant in the FTO gene did not modify the effect of lifestyle changes on body weight: the Finnish Diabetes Prevention Study. Obesity (Silver Spring) 2009; 17(4): 832-6.
70
Razquin C, Martinez JA, Martinez-Gonzalez MA, Bes-Rastrollo M, Fernandez-Crehuet J, Marti A. A 3-year intervention with a Mediterranean diet modified the association between the rs9939609 gene variant in FTO and body weight changes. Int J Obes (Lond) 2010; 34(2): 266-72.
71
Dlouha D, Suchanek P, Lanska V, Hubacek JA. Body mass index change in females after short-time life style intervention is not dependent on the FTO polymorphisms. Physiol Res 2011; 60(1): 199-202.
72
ORIGINAL_ARTICLE
Huge mass in right side of the heart: A rare case report
BACKGROUND: The presence of primary intracardiac tumors are scarce, and most of them are myxomas. We reported, in this paper, a case with huge mass in the right side of the heart. CASE REPORT: A 45-year-old man, with a complaint of bilateral lower limbs edema and exertional dyspnea, was admitted to intensive cardiac care unit. Cardiac auscultation revealed soft grade systolic murmur without any evidence of “tumor plop.” Echocardiography showed a huge mobile mass in right side of the heart that suggested myxoma. Our patient underwent cardiac surgery with excision of 13 cm mass. Histopathological study was confirmed the diagnosis of mass type. CONCLUSION: In this case report, it shows that in the differential diagnosis of right-sided heart failure, the right sided myxoma must be considered. The preferable approach in patient with cardiac myxomas is surgical excision to alleviate symptoms, early identification, and removal.
https://arya.mui.ac.ir/article_10557_d85244c6976c6896ed2c115ab70a712b.pdf
2017-02-01
291
294
Myxoma
Cardiac Surgery
Echocardiography
Case Report
Reza
Ghasemi
1
Assistant Professor, Department of Cardiology, Dey 9th Hospital, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
AUTHOR
Fahimeh
Ghanei-Motlagh
2
Department of Obstetrics and Gynecology, Qaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Susan
Nazari
3
Department of Obstetrics and Gynecology, Dey 9th Hospital, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
AUTHOR
Mohsen
Yaghubi
n.m.yaghubi@gmail.com
4
Department of Cardiac Anesthesiology, School of Medicine, Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Nina VJ, Silva NA, Gaspar SF, Raposo TL, Ferreira EC, Nina RV, et al. Atypical size and location of a right atrial myxoma: a case report.
1
J Med Case Rep 2012; 6: 26.
2
Jang KH, Shin DH, Lee C, Jang JK, Cheong S, Yoo SY. Left atrial mass with stalk: Thrombus or myxoma? J Cardiovasc Ultrasound 2010; 18(4): 154-6.
3
Vale Mde P, Freire Sobrinho A, Sales MV, Teixeira MM, Cabral KC. Giant myxoma in the left atrium: case report. Rev Bras Cir Cardiovasc 2008; 23(2): 276-8.
4
Diaz A, Di Salvo C, Lawrence D, Hayward M. Left atrial and right ventricular myxoma: an uncommon presentation of a rare tumour. Interact Cardiovasc Thorac Surg 2011; 12(4): 622-3.
5
Gribaa R, Slim M, Kortas C, Kacem S, Ben Salem H, Ouali S, et al. Right ventricular myxoma obstructing the right ventricular outflow tract: a case report. J Med Case Rep 2014; 8: 435.
6
Huang SC, Lee ML, Chen SJ, Wu MZ, Chang CI. Pulmonary artery myxoma as a rare cause of dyspnea for a young female patient. J Thorac Cardiovasc Surg 2006; 131(5): 1179-80.
7
Manfroi W, Vieira SR, Saadi EK, Saadi J, Alboim C. Multiple recurrences of cardiac myxomas with acute tumoral pulmonary embolism. Arq Bras Cardiol 2001; 77(2): 161-6.
8
Stolf NA, Benķcio A, Moreira L F, Rossi E. Right atrium myxoma originating from the inferior vena cava: An unusual location with therapeutic and diagnostic implications. Rev Bras Cir Cardiovasc 2000; 15(3): 255-8.
9
Samanidis G, Perreas K, Kalogris P, Dimitriou S, Balanika M, Amanatidis G, et al. Surgical treatment of primary intracardiac myxoma: 19 years of experience. Interact Cardiovasc Thorac Surg 2011; 13(6): 597-600.
10
Mann DL, Zipes DP, Braunwald E, Bonow RO. Braunwald's heart disease: A textbook of cardiovascular medicine. 10th ed. Philadelphia, PA: Elsevier/Saunders; 2015.
11
ORIGINAL_ARTICLE
Presentation of new classification of perceived risk factors and etiologies of cardiovascular diseases
-
https://arya.mui.ac.ir/article_10558_a588e286b650d1d6956e48e0b8b6f04f.pdf
2017-02-01
295
296
classification
perceived risk factors
Cardiovascular Diseases
Saeid
Komasi
1
Cardiac Rehabilitation Center, Imam Ali Hospital AND Clinical Research Development Center, Imam Reza Hospital AND Department of Psychology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
AUTHOR
Mozhgan
Saeidi
m_saeidi20@yahoo.com
2
PhD Candidate, Cardiac Rehabilitation Center AND Department of Psychology, School of Medicine, Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
LEAD_AUTHOR
Komasi S, Saeidi M. Aging is an important cause for a lack of understanding of the main risk factor in cardiac rehabilitation patients. Thrita 2015; 4(4): e32751.
1
Leventhal H, Meyer D, Nerenz D. The common sense representation of illness danger. In: Rachman S, Editor. Contributions to medical psychology. New York, NY: Pergamon Press; 1980.
2
Hagger MS, Orbell S. A meta-analytic review of the common-sense model of illness representations. Psychol Health 2003; 18(2): 141-84.
3
Saeidi M, Komasi S, Soroush A, Zakiei A, Shakeri J. Gender differences in patients' beliefs about biological, environmental, behavioral, and psychological risk factors in a cardiac rehabilitation program. J Cardiothorac Med 2014; 2(4): 215-20.
4
Saeidi M, Soroush A, Komasi S, Moemeni K, Heydarpour B. Attitudes toward cardiovascular disease risk factors among patients referred to a cardiac rehabilitation center: importance of psychological attitudes. Shiraz E Med J 2015; 16(7): e22281.
5
Saeidi M, Komasi S, Heydarpour B, Momeni K, Zakiei A. Those who perceive their disease as a physiological or psychological risk factor experience more anxiety at the beginning of the cardiac rehabilitation program. Res Cardiovasc Med 2016; 5(4): e29291.
6
ORIGINAL_ARTICLE
Myocardial bridging of the posterolateral branches of the right coronary artery
-
https://arya.mui.ac.ir/article_10559_6834ba91f4d102694776651a56a8c725.pdf
2017-02-01
297
298
Arash
Gholoobi
gholoobia@mums.ac.ir
1
Assistant Professor, Atherosclerosis Prevention Research Center, Imam Reza Hospital AND Department of Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Alegria JR, Herrmann J, Holmes DR Jr, Lerman A, Rihal CS. Myocardial bridging. Eur Heart J 2005; 26(12): 1159-68.
1
Okmen E, Oguz E, Erdinler I, Sanli A, Cam N. Left circumflex coronary artery bridging. Jpn Heart J 2002; 43(4): 423-7.
2
Celik T, Iyisoy A, Kursaklioglu H. Myocardial bridging confined to the right ventricular branch of the right coronary artery in a patient with severe pulmonary hypertension. J Invasive Cardiol 2006; 18(8): E223-E224.
3
Kumar B, Wardhan H, Nath RK, Sharma A. A rare case of myocardial bridge involving left main, left circumflex, and left anterior descending coronary arteries. J Am Coll Cardiol 2012; 59(10): 965.
4
Nguyen TH, Burnside PR, Dieter RS, Nanjundappa A. Right coronary artery distribution of myocardial bridging: an unusual case presenting with ST-Elevation myocardial infarction. Tex Heart Inst J 2007; 34(4): 489-91.
5
Mohlenkamp S, Hort W, Ge J, Erbel R. Update on myocardial bridging. Circulation 2002; 106(20): 2616-22.
6
ORIGINAL_ARTICLE
Journal Index
Click to download the index of this issue.
https://arya.mui.ac.ir/article_10551_d5d4bf77ee41a71b393feb1fa67d093c.pdf
2016-11-01
Index
Journal
arya@crc.mui.ac.ir
1
LEAD_AUTHOR